Advisors Capital Management LLC Acquires 6,648 Shares of Zoetis Inc. $ZTS

Advisors Capital Management LLC raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.7% in the third quarter, Holdings Channel reports. The institutional investor owned 149,485 shares of the company’s stock after acquiring an additional 6,648 shares during the period. Advisors Capital Management LLC’s holdings in Zoetis were worth $21,873,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in ZTS. Halbert Hargrove Global Advisors LLC grew its position in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the period. NewSquare Capital LLC grew its holdings in Zoetis by 69.1% during the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the period. Financial Consulate Inc. bought a new stake in Zoetis during the third quarter valued at about $39,000. SJS Investment Consulting Inc. raised its stake in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after buying an additional 257 shares during the period. Finally, TruNorth Capital Management LLC bought a new position in shares of Zoetis in the third quarter worth about $42,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

ZTS stock opened at $125.45 on Wednesday. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.00. The firm has a market capitalization of $52.96 billion, a P/E ratio of 20.84, a price-to-earnings-growth ratio of 2.12 and a beta of 0.96. The company has a fifty day simple moving average of $124.79 and a two-hundred day simple moving average of $135.06. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company earned $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s payout ratio is currently 35.22%.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Barclays began coverage on shares of Zoetis in a report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Stifel Nicolaus cut their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Finally, Morgan Stanley set a $160.00 price objective on Zoetis in a research report on Thursday, December 18th. Five analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.